Abstract
Paediatric cardiomyopathy and heart failure are distinct but frequently associated conditions, which have a high mortality. Traditional medical therapy has evolved to incorporate newer classes of heart failure drugs, although the evidence to support efficacy in children is limited. This perspective article discusses the rationale, benefits and limitations of the various classes of drug therapy used in paediatric heart failure due to cardiomyopathy or congenital heart disease. Controversies in management and challenges for future development are highlighted.
Copyright © 2011. Published by Elsevier Ltd.
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Cardiomyopathies / complications
-
Cardiotonic Agents / therapeutic use
-
Child
-
Digoxin / therapeutic use
-
Diuretics / therapeutic use
-
Heart Defects, Congenital / complications
-
Heart Failure / drug therapy*
-
Heart Failure / etiology
-
Humans
-
Hydrazones / therapeutic use
-
Natriuretic Peptide, Brain / therapeutic use
-
Pyridazines / therapeutic use
-
Simendan
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Cardiotonic Agents
-
Diuretics
-
Hydrazones
-
Pyridazines
-
Natriuretic Peptide, Brain
-
Simendan
-
Digoxin